BioLife Solutions insider reports 516-share tax withholding

BioLife Solutions executive Mathew Aby J., EVP & Chief Scientific Officer, reported a tax-withholding disposition of 516 shares of common stock on July 7, 2026.

Rhea-AI Filing Summary

BioLife Solutions executive Mathew Aby J., EVP & Chief Scientific Officer, reported a tax-withholding disposition of 516 shares of common stock on July 7, 2026. The shares were withheld by the company to satisfy tax obligations upon the release of restricted stock units, and Aby now holds 388,460 shares directly.

Filing Explained

The July 7 tax withholding left the reporting person with 388,460 directly held shares; the filing reports no issuer-level structural change.

BioLife Solutions reported that its EVP and Chief Scientific Officer, also identified as a 10% owner, had 516 shares of common stock withheld on 2026-07-07 for tax obligations, leaving 388,460 shares held directly after the transaction.

Under Form 4 mechanics, transaction code F denotes shares withheld to cover taxes on vesting; this is not reported as an open-market sale in the filing.

The filing explains that the withholding arose when restricted stock units were released, and it records the resulting direct holdings rather than a new issuer financing or derivative transaction.

Insider Trade Summary

Tax Withholding: 516 shares

Tax Withholding 1 txn

Insider Mathew Aby J.

Role EVP & Chief Scientific Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	516	$27.79	$14K

Holdings After Transaction: Common Stock — 388,460 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Key Figures

Shares withheld for taxes: 516 shares Per-share value for withheld shares: $27.79 per share Shares held after transaction: 388,460 shares +1 more

4 metrics

Shares withheld for taxes 516 shares Tax-withholding disposition of common stock on July 7, 2026

Per-share value for withheld shares $27.79 per share Value assigned to the 516 shares withheld for tax obligations

Shares held after transaction 388,460 shares Direct ownership of BioLife Solutions common stock following the withholding

Tax-withholding shares (summary) 516 shares TaxWithholdingShares reported in the transaction summary

Key Terms

tax withholding obligations, restricted stock units, tax-withholding disposition

3 terms

tax withholding obligations financial

"to satisfy tax withholding obligations of the reporting person"

restricted stock units financial

"arose upon the release of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax-withholding disposition financial

"transaction_action": "tax-withholding disposition""

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BLFS executive Mathew Aby J. report?

Mathew Aby J. reported a tax-withholding disposition of 516 shares of BioLife Solutions common stock on July 7, 2026. The issuer withheld these shares to cover tax obligations triggered by the release of restricted stock units, not through an open-market sale.

How many BLFS shares were withheld for taxes in this Form 4?

A total of 516 shares of BioLife Solutions common stock were withheld. The issuer retained these shares to satisfy the reporting person’s tax withholding obligations arising from the vesting and release of restricted stock units, a standard equity compensation mechanism.

At what price were the withheld BLFS shares valued in the transaction?

The 516 withheld shares were valued at $27.79 per share. This price is used solely for reporting the value of the shares applied to the tax withholding obligation tied to the restricted stock units’ release, not as an open-market sale price.

How many BLFS shares does Mathew Aby J. hold after this tax-withholding event?

Following the tax-withholding disposition, Mathew Aby J. holds 388,460 shares of BioLife Solutions common stock directly. This figure reflects his remaining direct ownership after 516 shares were withheld by the issuer for equity award–related tax obligations.

Was the BLFS insider transaction a sale on the open market?

No, the transaction was a tax-withholding disposition, not an open-market sale. The issuer withheld 516 shares to satisfy the reporting person’s tax liabilities from restricted stock units vesting, a common administrative step in equity compensation programs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 05:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mathew Aby J.

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WASHINGTON 98021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/07/2026		F		516(1)	D	$27.79	388,460	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Remarks:

	/s/ Aby J. Mathew	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)